Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2022 | The efficacy of cevostamab in R/R multiple myeloma and the importance of bispecific antibodies

Amrita Krishnan • 29 Sep 2022
SOHO 2022
Multiple Myeloma Antibodies BiTEs Cevostamab Talquetamab Teclistamab

Amrita Krishnan, MD, City of Hope, Duarte, CA, gives an overview of the safety and efficacy of cevostamab in patients with relapsed/refractory (R/R) multiple myeloma, and further highlights the importance of bispecific antibodies in this disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Amrita Krishnan

Real-world evidence of outcomes of heavily pretreated patients with myeloma treated with talquetamab 1:43
Real-world evidence of outcomes of heavily pretreated patients with myeloma treated with talquetamab
Amrita Krishnan • 6 Dec 2024
The future of bispecifics for myeloma: talquetamab combinations 0:44
The future of bispecifics for myeloma: talquetamab combinations
Amrita Krishnan • 6 Dec 2024
Encouraging the integration of bispecifics into routine clinical practice 0:57
Encouraging the integration of bispecifics into routine clinical practice
Amrita Krishnan • 6 Dec 2024
Sequencing of BCMA-directed therapies for multiple myeloma 1:21
Sequencing of BCMA-directed therapies for multiple myeloma
Amrita Krishnan • 2 Jun 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals